FY2025 · ended Dec 31, 2025 · Revenue $33.59M, +19.7% YoY · Filed Mar 12, 2026
Rapid Micro Biosystems, Inc. (RPID) files with the SEC under industry code 3826, Laboratory Analytical Instruments. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $33.6 million and a net loss of $47.1 million. Free cash flow was -$31.9 million. As of Jun 30, 2026 it held $19.8 million in cash and investments and $23.5 million in total debt.
Revenue (TTM)
$35.18M
+16.1% vs year-ago TTM
Net income (TTM)
$-51.20M
-16.1% vs year-ago TTM
Operating cash flow (TTM)
$-40.06M
-7.5% vs year-ago TTM
Free cash flow (TTM)
$-40.39M
-5.5% vs year-ago TTM
EPS (TTM)
$-1.11
-11.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
—
Net cash
$-3.71M
as of Jun 30, 2026
Operating margin
-141.5%
FY 2026
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- RPID (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Lexington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1380106
- Former names
- RAPID MICRO BIOSYSTEMS INC (until Jul 15, 2009)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $33.6M | $28.1M | $22.5M | $17.1M | $23.2M |
| Operating income | -$47.4M | -$49.9M | -$56.6M | -$63.2M | -$47.2M |
| Net income | -$47.1M | -$46.9M | -$52.5M | -$60.8M | -$73.5M |
| Diluted EPS | -$1.05 | -$1.08 | -$1.22 | -$1.43 | -$3.94 |
| Operating cash flow | -$31.1M | -$44.2M | -$45.1M | -$58.5M | -$55.0M |
| Free cash flow | -$31.9M | -$45.5M | -$46.9M | -$65.3M | -$58.2M |
| Total assets | $74.9M | $98.2M | $143.5M | $190.7M | $241.2M |
| Total liabilities | $41.6M | $22.8M | $25.5M | $26.5M | $20.2M |
| Stockholders' equity | $33.2M | $75.4M | $118.0M | $164.2M | $221.0M |
| Cash and investments | $38.3M | $50.7M | $95.0M | $138.4M | $203.5M |
| Total debt | $23.9M | $6.2M | $7.3M | $8.0M | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 28, 2026 | May 21, 2026 |
| 8-K |
Current report
Material agreement
|
May 19, 2026 | May 18, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
All 328 Rapid Micro Biosystems, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.